Evidence map›Paper›PMID 37635867›Full record

ReviewFrontiers in cell and developmental biology2023

JAK/STAT signaling in diabetic kidney disease.

Yingjun Liu, Wenkuan Wang, Jintao Zhang, Shuo Gao, Tingting Xu, Yonghui Yin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. [Rehmanniae radix preparata alleviates chronic kidney disease in mice through a multi-target mechanism].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Association of Janus kinase 1 and 2 expression with clinical indices in diabetic kidney disease.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yingjun LiuClinical Medicine Department, Shandong University of Traditional Chinese Medicine, Jinan, China.
Wenkuan WangClinical Medicine Department, Shandong University of Traditional Chinese Medicine, Jinan, China.
Jintao ZhangClinical Medicine Department, Shandong University of Traditional Chinese Medicine, Jinan, China.
Shuo GaoClinical Medicine Department, Shandong University of Traditional Chinese Medicine, Jinan, China.
Tingting XuClinical Medicine Department, Shandong University of Traditional Chinese Medicine, Jinan, China.
Yonghui YinDepartment of Endocrinology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic kidney disease (DKD) is the most important microvascular complication of diabetes and the leading cause of end-stage renal disease (ESRD) worldwide. The Janus kinase/signal transducer and activator of the transcription (JAK/STAT) signaling pathway, which is out of balance in the context of DKD, acts through a range of metabolism-related cytokines and hormones. JAK/STAT is the primary signaling node in the progression of DKD. The latest research on JAK/STAT signaling helps determine the role of this pathway in the factors associated with DKD progression. These factors include the renin-angiotensin system (RAS), fibrosis, immunity, inflammation, aging, autophagy, and EMT. This review epitomizes the progress in understanding the complicated explanation of the etiologies of DKD and the role of the JAK/STAT pathway in the progression of DKD and discusses whether it can be a potential target for treating DKD. It further summarizes the JAK/STAT inhibitors, natural products, and other drugs that are promising for treating DKD and discusses how these inhibitors can alleviate DKD to explore possible potential drugs that will contribute to formulating effective treatment strategies for DKD in the near future.

Indexed as

diabetic kidney diseaseetiologyinhibitorJAK/STAT signalingtreatment strategy

Identifiers

PMID37635867
PMCPMC10450957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.